Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | TGM1 | P22735 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26673612 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HSD11B1 | |
| SCHEMBL4035476 | 0.84 | HSD11B1 (0.59) | KMT2AMEN1MAOAALDH1A1LMNA | |
| SCHEMBL6728595 | 0.77 | F10 (0.49) | — | |
| SCHEMBL3771947 | 0.77 | STS (0.50) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL24072164 | 0.77 | RAB9A (0.58) | NPC1NR2F2RAB9AKMT2AMEN1 | |
| SCHEMBL24072645 | 0.76 | RAB9A (0.60) | NPC1NR2F2RAB9AKMT2AMEN1 | |
| SCHEMBL26673650 | 0.76 | NR1H2 (0.61) | KMT2AALDH1A1 | |
| SCHEMBL24072648 | 0.76 | RAB9A (0.77) | NPC1NR2F2RAB9AKMT2AMEN1 | |
| SCHEMBL24071820 | 0.75 | NPC1 (0.64) | NPC1NR2F2RAB9AKMT2AMEN1 | |
| SCHEMBL18064023 | 0.74 | NR1H2 (0.54) | KMT2AALDH1A1LMNAHSD11B1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| EP-4157263-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | The Regents Of The University Of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2021242753-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | NPC1 1157/4885NR2F2 2589/4885RAB9A 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.